Cost-effectiveness analysis, welfare economics, and the societal perspective: a reply

被引:0
|
作者
Bengt Liljas
机构
[1] AstraZeneca,Department of Economics
[2] Lund University,undefined
关键词
Cost-effectiveness analysis; QALYs; Welfare economics; Societal perspective; D61; D81; I10;
D O I
暂无
中图分类号
学科分类号
摘要
A critical question in cost-effectiveness analysis (CEA) is what costs should be included. In an earlier paper in this journal, I argued that the same principle (internal consistency) that has been applied to the discussion about future non-medical costs should also be applied to the case when survival is not affected. Internal consistency in this case implies that a cost should only be included if its corresponding utility is also included. As Quality-Adjusted Life-Years can rarely be considered to be consistent with a broad definition of utility, I built a case for recommending to not including the costs for changes in consumption and absence from work (whereas changes in the productivity at work may still be included) when applying a welfare theoretic foundation. As one of several parts of building this case, and to further highlight the elements of importance, I constructed a simple welfare theoretic model. Unfortunately, this model did not take the envelope theorem into account (which was correctly pointed out by Prof. Friedrich Breyer). However, most of the arguments still hold and the policy implications are actually even confirmed in the analysis by Prof. Friedrich Breyer. Building on these results, a related and equally interesting question is what the implications are on the so-called societal perspective. It seems as if a societal perspective in CEA may not be consistent with a welfare theoretic foundation. However, even if such a foundation is not seen as important, it may still be of interest—for reasons of internal consistency—to take a societal perspective on both costs and benefits.
引用
收藏
页码:597 / 598
页数:1
相关论文
共 50 条
  • [21] Cost-effectiveness - Reply
    Stewart, William C.
    Stewart, Jeanette A.
    Nasser, Qasiem
    Mychaskiw, Marko A.
    OPHTHALMOLOGY, 2008, 115 (10) : 1853 - 1853
  • [22] Drug Pricing, Patient Welfare, and Cost-Effectiveness Analysis
    van Baal, Pieter
    Barros, Pedro Pita
    VALUE IN HEALTH, 2024, 27 (03) : 271 - 272
  • [23] Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective
    Chevalier, Julie
    Chamoux, Catherine
    Hammes, Florence
    Chicoye, Annie
    PLOS ONE, 2016, 11 (03):
  • [24] Cost-Effectiveness of Duloxetine in Chronic Low Back Pain A Quebec Societal Perspective
    Wielage, Ronald
    Bansal, Megha
    Wilson, Kinsley
    Klein, Robert
    Happich, Michael
    SPINE, 2013, 38 (11) : 936 - 946
  • [25] The negative side of cost-effectiveness analysis - Reply
    Obenchain, RL
    Sacristan, JA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24): : 1932 - 1933
  • [26] Cost-effectiveness analysis in the United States - Reply
    Pearson, SD
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (23): : 2722 - 2723
  • [27] Cost-effectiveness analysis and budget constraints - Reply
    Ubel, PA
    Asch, DA
    Baron, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (19): : 1466 - 1466
  • [28] Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective
    Mantovani, Lorenzo Giovanni
    Furneri, Gianluca
    Bitonti, Rossella
    Cortesi, Paolo
    Puma, Elisa
    Santoni, Laura
    Prosperini, Luca
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2019, 20 (01) : 73 - 86
  • [29] Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score ® Test from a US Societal Perspective
    Berdunov, Vladislav
    Carter, Gebra Cuyun
    Laws, Ewan
    Luo, Roger
    Russell, Christy A.
    Campbell, Sara
    Abdou, Yara
    Force, Jeremy
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2024, 16 : 471 - 482
  • [30] Cost-effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients with Metastatic Prostate Cancer: A Societal Perspective
    Rezaee, Mehdi
    Karimzadeh, Iman
    Hashemi-Meshkini, Amir
    Zeighami, Shahryar
    Bazyar, Mohammad
    Lotfi, Farhad
    Keshavarz, Khosro
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 42